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ARTICLE
Metformin enhances anti-mycobacterial responses
by educating CD8+ T-cell immunometabolic
circuits
Julia Böhme1, Nuria Martinez2, Shamin Li1,3, Andrea Lee1, Mardiana Marzuki1, Anteneh Mehari Tizazu1,
David Ackart4, Jessica Haugen Frenkel4, Alexandra Todd4, Ekta Lachmandas5, Josephine Lum1, Foo Shihui1,
Tze Pin Ng6, Bernett Lee1, Anis Larbi1, Mihai G. Netea 5,7, Randall Basaraba4, Reinout van Crevel5,
Evan Newell 1,3, Hardy Kornfeld 2 & Amit Singhal 1,8,9,10✉
Patients with type 2 diabetes (T2D) have a lower risk of Mycobacterium tuberculosis infection,
progression from infection to tuberculosis (TB) disease, TB morality and TB recurrence, when
being treated with metformin. However, a detailed mechanistic understanding of these
protective effects is lacking. Here, we use mass cytometry to show that metformin treatment
expands a population of memory-like antigen-inexperienced CD8+CXCR3+ T cells in naive
mice, and in healthy individuals and patients with T2D. Metformin-educated CD8+ T cells
have increased (i) mitochondrial mass, oxidative phosphorylation, and fatty acid oxidation;
(ii) survival capacity; and (iii) anti-mycobacterial properties. CD8+ T cells from Cxcr3−/−
mice do not exhibit this metformin-mediated metabolic programming. In BCG-vaccinated
mice and guinea pigs, metformin enhances immunogenicity and protective efficacy againstM.
tuberculosis challenge. Collectively, these results demonstrate an important function of CD8+
T cells in metformin-derived host metabolic-fitness towards M. tuberculosis infection.
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Tuberculosis (TB) is a major threat to global health owing tothe inadequacies of antimicrobial treatment, the lack of ahighly effective preventive or therapeutic vaccine, and the
rise of drug-resistant Mycobacterium tuberculosis (Mtb) infection.
Interest is now focused on a new therapeutic paradigm, host-
directed therapies (HDT) for TB, to boost the antimicrobial
efficacy of innate and adaptive immunity to TB while limiting
excessive inflammation and tissue damage1,2.
Patients with type 2 diabetes mellitus (T2D) have reduced risk
of severe TB disease3 and Mtb infection when treated with met-
formin4. Metformin enhances the efficacy of anti-TB drugs,
ameliorates lung pathology and reduces inflammation in Mtb-
infected mice3. Retrospective data from eight clinical cohorts
comprising a combined >250,000 individuals treated with met-
formin for T2D showed that metformin reduces the risk for
progression to TB disease, mortality, lung cavitation, and relapse,
and that it accelerates sputum conversion independently of gly-
cemic control3–9. Metformin is a top candidate in the TB-HDT
pipeline, but a detailed mechanistic understanding of its protec-
tive immunometabolic benefits is lacking.
Although CD4+ T cells are generally recognized as the pre-
dominant effectors of adaptive immunity to TB, CD8+ T cells are
also recognized to play a critical role in determining whether the
Mtb infection is contained or progresses to active disease10. Upon
infection, naive CD8+ T cells (TN) differentiate into antigen (Ag)-
specific effector T cells (TE) and central memory T cells (TCM).
The latter have the ability to survive, expand, and generate
cytotoxic CD8+ TE cells upon encounter with a cognate Ag later
in life11. These TCM are the major memory-like T cells in an
infected or an immunized host. In contrast, in naive mice housed
under specific-pathogen free conditions, Ag-inexperienced
memory-like CD8+ T-cell (TM) population, sometimes known
as virtual-memory (TVM) or innate-memory CD8+ T cells, have
been described12–14. These Ag-inexperienced CD8+ TM cells (i)
display unique and similar phenotypes to Ag-experienced CD8+
TCM cells13–16, (ii) rapidly respond to primary antigenic stimuli14,
and (iii) mediate the protective immunity via non-canonical
effector functions17.
Survival, activation, and effector function of T cells is funda-
mentally linked to cellular metabolic programming18. TE cells
predominantly use glycolysis, whereas TCM cells use oxidative
phosphorylation (OXPHOS) to meet energy demands18,19. CD8+
TCM exhibit increased mitochondrial fatty-acid oxidation (FAO),
spare respiratory capacity (SRC), and biogenesis20. SRC is the
reserve capacity to produce energy in the mitochondria beyond
the basal state. The increase in FAO required for optimal CD8+
TCM generation and survival depends on the mitochondrial
import of long chain fatty acids20,21. Of note, CD8+ TCM cells
have been recently demonstrated to have lower SRC than CD8+
TVM cells22.
In this study, we identify that metabolic reprograming by
metformin empowers CD8+ T cells to contain Mtb infection. We
show that metformin treatment (i) expands memory-like CD8+
CXCR3+ T cells in naive mice and in healthy and diabetic
humans, (ii) induces mitochondrial SRC and FAO in CD8+
T cells, and (iii) enhances Bacillus Calmette–Guérin (BCG)
vaccine-elicited CD8+ T-cell responses and efficacy in mouse and
guinea pig TB models. Metformin-educated Ag-inexperienced
CD8+ TM cells have gene expression signatures similar to an
activated T cells, and restrict Mtb growth in T-cell-deficient mice.
Results
Metformin-educated CD8+ T cells restrict Mtb replication. We
previously reported that metformin attenuates immunopathology
and reprograms CD4+ and CD8+ T-cell responses in tissues of
Mtb-infected wild-type C57BL/6 (WT) mice3. To dissect the
relative importance of metformin-educated CD4+ vs CD8+
T cells in TB defense, we compared their capacity to protect
against Mtb infection in an adoptive transfer model. Splenic
CD4+ or CD8+ T cells from WT mice treated with metformin or
not (control group) were isolated and adoptively transferred into
irradiated recipients, which were then infected with Mtb (Fig. 1a).
Irradiated naive recipients that did not receive any T cells were
also infected (no transfer group). In two independent experiments
we found that mice which received metformin-educated CD8+
T cells had 0.5 log10 reduced lung bacterial load at 21 days post
infection (p.i.) compared with the mice that did not receive any
T cells (Fig. 1b, c). At the same time, we noticed a 0.3 log10
reduction in the lungs of mice receiving metformin-educated
CD8+ T cells compared to those receiving CD8+ T cells from
untreated mice (Fig. 1b, c). In these experiments, CD4+ T cells
from metformin-treated and untreated donors failed to mediate
the protection against Mtb (Fig. 1b, c).
The reduction in the lung bacterial load in recipients of
metformin-educated (or metformin-primed) CD8+ T cells was
paralleled by an increased frequency and total numbers of splenic
memory CD8+CD44+CD62L+ T cells and naive CD8+CD44−
CD62L+ T cells, and decreased effector CD8+CD44+CD62L−
T cells compared to the mice that did not receive CD8+ T cells
(Fig. 1d, e and Supplementary Fig. 1a). Of note, there was no
change in the total number of CD3+, CD4+, and CD8+ T cells in
the recipient mice among different groups (Supplementary Fig. 1b).
These results suggested that the predominant effect of metformin
treatment in donor mice was on the memory compartment of
CD8+ T cells over effector compartment, as more memory cells
were observed within the total CD8+ splenic T cells from Mtb-
infected recipients receiving metformin-educated CD8+ T cells. In
contrast, the proportions of memory to effector CD8+ T cells were
equal in the spleens of Mtb-infected mice that received control
CD8+ T cells (Fig. 1e). Mice receiving either metformin-educated
or control CD8+ T cells had increased frequencies of perforin-
expressing (Perforin+IFNγ−TNF−) memory CD8+ T cells com-
pared with the mice that did not receive any T cells (Fig. 1f). In
congenic recipients (receiving either metformin-educated or control
CD8+ T cells) we saw similar increased numbers of Perforin+
IFNγ− donor memory CD45.1+CD8+ T cells compared with the
mice that did not receive any T cells (Fig. 1g and Supplementary
Fig. 1c). Surprisingly, mice receiving metformin-educated CD8+
T cells had increased numbers of double- or triple-negative memory
CD8+ T cells (Fig. 1f, g), indicating perforin-, IFNγ- and TNF-
independent Mtb killing property of metformin-educated CD8+
T cells. CD4+ T cells have been reported to have such non-
canonical anti-Mtb property23. Overall, these results demonstrated
the anti-Mtb activity of metformin-educated CD8+ T cells and
suggested the potential of metformin to induce the expansion of
memory CD8+ T cells with a unconventional effector phenotype.
Metformin expands CD8+CXCR3+ TM cell population in
naive mice. To understand the effects of metformin exposure on
CD8+ T cells in naive mice, we investigated the phenotype of
metformin-educated splenic CD8+ T cells by mass cytometry
(CyTOF)24,25 using a panel of 40 markers (Fig. 2a and Supple-
mentary Table 1). Analysis of live CD45+CD19−TCRβ+CD90+
CD4−CD8+ spleen cells (Supplementary Fig. 2a) using the
nonlinear dimensionality reduction technique t-SNE with a
machine-learning clustering algorithm (Phenograph) identified
20 distinct cell clusters with different expression characteristics of
surface markers and intracellular transcription factors (Fig. 2b, c
and Supplementary Fig. 2b). Based on the expression of CD62L
and CD44, 20 clusters of CD8+ T cells were broadly classified
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into TN, TE, and TM cells (Fig. 2b and Supplementary Fig. 2b).
Automated machine-learning gating showed an expansion in the
proportion of cells in clusters 9, 12 and 18, which comprised all
TM cells, within the total metformin-educated CD8+ T-cell
population (Supplementary Fig. 2c). These clusters were strongly
positive for conventional and unconventional memory T-cell
markers including CD62L, CD44, CD127, CD27, CD122, and
Eomes (Fig. 2c and Supplementary Fig. 2b). They also expressed
Tbet, CXCR3 and CD49d (Fig. 2c and Supplementary Fig. 2b),
indicating an effector phenotype and differentiating them from
CD8+ TVM cells15,26. Tbet directly transactivates CXCR327 and
retroviral-mediated CXCR3 expression in Tbet−/− CD8+ T cells
reconstitutes their ability to infiltrate inflamed tissues28. CXCR3
plays an important role in T-cell trafficking and function26 and
expression of CXCR3 on CD8+ TM cells is critical for populating
the airways under steady state conditions29.
Using a manual gating strategy, we validated the enrichment of
CD8+ TM cells identified by machine-learning strategy, confirm-
ing an increased frequency of memory-like CD8+CXCR3+ cells
after metformin treatment (Fig. 2d). The enhanced CD8+ TM
frequency induced by metformin was further confirmed by flow
cytometry of splenocytes from naive mice (Fig. 2e, f). Flow
cytometric analysis also showed an enhanced frequency of total
CD8+CXCR3+ cells in the spleen of metformin-treated naive
mice (Supplementary Fig. 2d). Interestingly, OVA protein-
stimulated CD8+ OT-I cells cultured with IL-15 (a cytokine
known to stimulate TM cell differentiation30) showed increased
TCM/TE ratio in the presence of metformin (Supplementary
Fig. 3a, b), further demonstrating effectiveness of metformin in
expanding the CD8+ TCM compartment as well.
We next used CyTOF to decipher the heterogeneity in the
lung CD8+ T cells from metformin-treated naive WT mice
gfe
a b c d
Fig. 1 Metformin-educated CD8+ T cells protect against M. tuberculosis. a Experimental strategy and assessed readouts. b, c Bacterial load in the lung
of recipient mice 21 days post transfer, from two different experiments. No transfer—Irradiated recipients that did not receive any cells. Metformin-
educated—CD4+ or CD8+ cells from donor mice treated with metformin; Control—cells from untreated mice. n= 5–6 mice/group/experiment. d Flow
cytometric analysis of splenic CD8+ T cells from mice of experiment 1 b. TM - memory T cells, CD44+CD62L+; TE effector T cells, CD44+CD62L−; TN -
naive T cells, CD44−CD62L+. e Frequency and number of CD8+ TE, TM, and TN cells in the recipient mice of experiment 1. n= 5 mice/group. f Frequency
and number of IFNγ+, TNF+, or Perforin+ CD8+ TM cells from e. n= 5 mice/group. g Frequency and number of IFNγ+ and/or Perforin+ CD45.1+CD8+ TM
cells in the recipient mice of experiment 2. n= 5 mice per group. Box-and-whisker plots show the median, 5 and 95 percentiles. All data are analyzed using
Kruskal–Wallis test with Dunn’s multiple comparison.
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(Supplementary Fig. 4a). Machine-learning analysis showed
metformin-mediated increased expression of CXCR3 on lung (i)
total CD8+ T cells (Supplementary Fig. 4b), (ii) CD8+ TE cells
(Supplementary Fig. 4c) and CD8+ TM cells (Fig. 2g). This was
further confirmed by manual gating of lung CyTOF data
(Supplementary Fig. 4d) and flow cytometric analysis of lung cells
(Supplementary Fig. 4e) from metformin-treated naive mice. To
test if CXCR3 was involved in the metformin-mediated expansion
of CD8+ TM cells in the spleen and lung, we compared untreated
and metformin-treated Cxcr3−/− mice. The Cxcr3−/− mice had
increased CD8+ TE and reduced CD8+ TM cells compared with
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confirming an earlier report31, while in the present study
metformin treatment did not alter the percentage of TE, TM, or
TN cells in Cxcr3−/− mice.
To determine why metformin failed to expand CD8+ TM cells
in Cxcr3−/− mice, we performed RNA sequencing (RNAseq) on
splenic CD8+ T cells from Cxcr3−/− and WT mice. We found
202 differentially expressed genes (DEGs) in CD8+ T cells from
Cxcr3−/− compared with WT mice (Fig. 2i, left panel and
Supplementary Data 1). Ingenuity pathway analysis (IPA) of
these DEGs revealed an enrichment of genes associated with
communication between innate and adaptive immune cells and
IL-7 signaling pathway (Fig. 2i, right panel and Supplementary
Table 2). For optimal CD8+ TM cell homeostasis a discontinuous
IL-7 signaling has been proposed32. Among DEGs, we found
downregulation of Foxo1 (Forkhead Box O1), Gsk3b (Glycogen
synthase kinase 3 beta) and Nkg7 (Natural killer cell granule
protein 7, a cytotoxic marker), and upregulation of Myc, Jun, and
Il1b (Interleukin 1 beta; Supplementary Data 1). Importantly,
FOXO1, GSK3B, and Myc are required in the maintenance of
memory state of CD8+ T cells33–35. Further analysis of DEGs
revealed a significant enrichment of FOXO1 targets (n= 35)36
among 202 DEGs (Fig. 2j, P= 1.2 × 106, hypergeometric test, see
“Methods”), indicating a perturbation in FOXO1 signaling in
CD8+ T cells from Cxcr3−/− mice. Taken together, our data
suggested that metformin reprograms the CD8+ T cells pheno-
type and shapes the generation of the CD8+CXCR3+ TM
population. This generation of CD8+CXCR3+ TM cells could
be mediated by FOXO1, which can also control CD8+ TM
responses during infection37.
Metformin promotes CD8+ T-cell SRC and mitochondrial
health. Enrichment of CD8+ TM cells by metformin suggested an
effect dependent on the regulation of cellular metabolism.
Therefore, we measured the bioenergetic profiles of spleen CD8+
T cells from untreated and metformin-treated naive WT mice.
Oxygen consumption rate (OCR), an indicator of OXPHOS, was
higher in metformin-treated CD8+ T cells compared to untreated
CD8+ T cells (Fig. 3a). Importantly, metformin-treated CD8+
T cells demonstrated a larger mitochondrial SRC when compared
with CD8+ T cells from untreated mice (Fig. 3a). This increase in
SRC was found to be dependent on CXCR3 expression (Fig. 3b).
The absence of metformin-mediated increased OXPHOS in
CD8+ T cells from Cxcr3−/− mice could be owing to the inherent
reduced expression of Foxo1 in these cells (Fig. 2i). Of note,
FOXO1 regulates oxidative stress responses, proliferation, cell
survival, and apoptosis, and connects metabolic activity with
immune response38–40.
Enhanced SRC in cells might be explained by increased cellular
mitochondrial mass20. CD8+ T cells from metformin-treated WT
mice showed increased Mitotracker Green median fluorescence
intensity (MFI) compared with CD8+ T cells from untreated
mice, indicating increased mitochondrial mass (Fig. 3c and
Supplementary Fig. 5a). Metformin-educated CD8+ T cells from
WT mice also showed a trend of increased mRNA expression
for Sell (CD62L), Cpt1a and Tfam (mitochondrial transcription
factor A) genes (Supplementary Fig. 5b). In addition, metformin-
educated CD8+ T cells showed increased accumulation of
tetramethylrhodamine, methyl ester (TMRM), indicating healthy
and functional mitochondria (Fig. 3d).
Metformin promotes survival of CD8+ T cells. To further assess
the impact of metformin on the CD8+ TM compartment, we
characterized the survival capacity of CD8+ T cells in vivo by
adoptively transferring metformin-treated or untreated cells into
congenic mice (Fig. 3e). After 3 days, we found significantly more
CD45.1+ donor metformin-treated CD8+ T cells in spleen and
lymph node of the recipient mice (Fig. 3f). Together, our data
suggested that metformin enhanced mitochondrial SRC and
health of CD8+ T cells and promoted their survival, which are
characteristic features of TM cells.
Metformin-educated CD8+ T cells use glucose for FAO and
OXPHOS. As metformin promoted the enrichment of the CD8+
TM cells (Fig. 2) with increased SRC (Fig. 3a), we reasoned that
metformin-educated CD8+ T cells might utilize extracellular
glucose to fuel mitochondrial FAO and OXPHOS, a property of
IL-15-induced CD8+ TM cells20. We evaluated this by measuring
OCR in CD8+ T cells cultured in low glucose (LG) medium. The
increased OCR and SRC seen in CD8+ T cells from metformin-
treated mice cultured in glucose-sufficient medium (25 mM,
Fig. 3a) was not observed under LG conditions (0.5 mM, Fig. 3g).
This suggested that glucose was driving FAO and OXPHOS in
metformin-educated CD8+ T cells. In addition, under LG con-
ditions, supplementation with fatty acid (palmitate) rescued the
SRC of metformin-educated CD8+ T cells (Fig. 3g), indicating
that increased SRC of metformin-educated CD8+ T cells in
glucose-sufficient media (Fig. 3a) was derived from FAO.
Next, we used the CPT1a inhibitor etomoxir (Eto), which
blocks mitochondrial FAO, to confirm that the enhanced SRC in
CD8+ T cells from metformin-treated mice depended on FAO.
Treatment with Eto, either before or after carbonylcyanide-p-
trifluoromethoxyphenylhydrazone (FCCP) injection, impaired
basal OCR and SRC, respectively, in metformin-educated CD8+
T cells (Fig. 3h, i). As CPT1a-independent effects of Eto on
mitochondrial respiration have been observed41 and we used
higher concentration of Eto (viz. 200 μM), FAO independent
effect of metformin on OXPHOS cannot be ruled out. To further
support the hypothesis that metformin-educated CD8+ TM cells
used glucose for FAO and OXPHOS, we performed glucose
uptake assay using the fluorescent glucose analog 2-NBDG. Lung
and spleen CD8+ TM cells from metformin-treated mice acquired
more 2-NBDG than CD8+ TM cells from untreated mice (Fig. 3j).
We did not find an increased uptake of 2-NBDG by CD8+ TE
Fig. 2 Metformin treatment expands CD8+CXCR3+ TM cell population in spleen and lungs of mice. a Experimental set-up of in vivo experiments.
b Visualized t-SNE map of CD8+ T cells from spleen of wild-type (WT) mice with automated cluster gating. t-SNE was performed on live CD45+CD90+
TCRαβ+CD4−CD8+ cells after gating out B cells. c Normalized expression intensities of indicated marker was calculated and overlaid on the t-SNE plot,
characterizing all clusters of CD8+ T cells in spleen. Means ± SD of four mice per group, one-tailed Mann–Whitney U test. d Manual gating analysis of
CD8+CXCR3+ TM cells in control and metformin-treated WT mice. e, f Flow cytometric analysis of splenic CD8+ T-cell subsets from control and
metformin-treated WT mice. Pooled data from three independent experiments. Means ± SD of n= 13–15 mice per group, two-tailed Mann–Whitney U test.
g Heat map displaying frequency of various surface markers in lung CD8+ T cells of control and metformin-treated WT mice. n= 4. *p≤ 0.05 by two-tailed
paired t test. h Flow cytometric analysis of spleen CD8+ TE, TM, and TN cells of control and metformin-treated Cxcr3−/− mice. Data shown one out of two
experiments, mean ± SD of five mice per group. i Left—volcano plot showing DEGs from RNA sequencing data of CD8+ T cells from Cxcr3−/− and WT
mice. n= 5 mice/group. Right—Canonical pathway enrichment via Ingenuity pathway analysis (IPA) of 202 DEGs. j Heat map displaying the expression
level of 35 FOXO1 targets in data shown in i. NS not significant.
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cells from metformin-treated mice (Supplementary Fig. 5c),
indicating minimal effect of metformin on the metabolic
reprogramming of those cells. Together, our data suggested that
glucose fuels mitochondrial FAO, which might be responsible
for the induction of OXPHOS in metformin-educated CD8+
T cells.
Distinct gene expression in metformin-educated CD8+ TM
cells. We next used RNAseq to characterize the effect of met-
formin on splenic CD8+ TM cells (Fig. 4a). A total of 267 genes
were found to be differentially expressed in metformin-educated
CD8+ TM cells (Fig. 4a and Supplementary Data 2). IPA-based
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on the expression of 86 genes associated with cell survival (Fig. 4b
and Supplementary Table 3). Among these 86 genes we found an
upregulation of Cdk1 (cyclin-dependent kinase 1) and Agap2
(Arf-GAP with GTPase, ANK repeat and PH domain-containing
protein 2) genes, consistent with a role of metformin in mod-
ulating CD8+ TM cell fate (Fig. 4c). In addition, metformin
reduced the expression of Mtor (mammalian target of rapamy-
cin), Immt (inner membrane mitochondrial protein, mitofilin),
and Casp1 (caspase-1) genes (Fig. 4c). Metformin is known to
inhibit mTOR42, whereas IMMT deficiency has been associated
with perturbed mitochondrial function43. As caspase-1 is
required for pyroptosis, a form of programmed cell death44, we
reasoned that the enhanced survival of metformin-educated
CD8+ T cells (Fig. 3f) might be explained by the reduced caspase-
1 activity. As predicted, metformin-treated Mtb-infected mice
had reduced numbers of CD8+caspase-1+ cells in the spleen
compared to the untreated Mtb-infected mice (Fig. 4d).
To test whether metformin-educated CD8+ TM cells survived
better in vivo under infection settings, we adoptively transferred
flow-sorted CD8+ TM cells into congenic TCRβδ−/− mice that were
subsequently infected with Mtb or BCG (Fig. 4e; total three
experiments). We found significantly more metformin-educated
donor cells in the lungs (Fig. 4f) and spleens (Fig. 4g) of the
recipientMtb-infected TCRβδ−/− mice. This paralleled with a trend
for lower bacterial load in the lungs of Mtb-infected TCRβδ−/−
mice that received metformin-educated CD8+ TM cells compared
with those receiving control CD8+ TM cells (1.4 log10 reduction),
although this did not reach statistical significance (Fig. 4h). In other
experiments, TCRβδ−/− mice receiving metformin-educated CD8+
TM cells had significantly lower lung and spleen bacterial load
compared with the TCRβδ−/− mice that did not receive any T cells
(0.9-1.3 log10 reduction; Fig. 4i, j). In this experiment, CD8+ TE
cells from control and metformin-treated mice equally restricted
lung bacterial loads in the TCRβδ−/− recipient mice to a
comparable level (Fig. 4i). Collectively, our data indicated that
metformin reprogramed gene expression of CD8+ TM cells,
increasing their survival and anti-mycobacterial properties.
Metformin enhances BCG vaccine immunogenicity and efficacy.
The generation of TM cells has important implications for vaccine
efficacy. As metformin-educated CD8+ TM cells display distinct
phenotypes and function associated with host protection, we eval-
uated the effect of metformin on the response to vaccination with
BCG (Supplementary Fig. 6a). In BCG-vaccinated mice, metformin
treatment was associated with an increased frequency of PPD
(purified protein derivative of Mtb)-specific IFNγ-secreting splenic
CD8+ T cells (Fig. 5a) but not CD4+ T cells (Supplementary
Fig. 6b), compared with untreated BCG-vaccinated animals. Similar
trend was observed in PPD-specific CD8+ TM and TE cells from
metformin-treated BCG-vaccinated mice (Fig. 5a). We also
observed an increased frequency of IFNγ+ total CD8+ cells
(unstimulated) from metformin-treated BCG-vaccinated mice
(Fig. 5a). CD8+ T cells from metformin-treated BCG-vaccinated
mice also demonstrated an increased mitochondrial mass (Fig. 5b)
and health (Fig. 5c) similar to that seen in unvaccinated animals
(Fig. 3b, c). We next performed RNAseq on flow-sorted CD8+ TM
cells from metformin-treated and untreated BCG-vaccinated mice.
Comparative analysis revealed 607 DEGs that were enriched for
genes associated with OXPHOS (Fig. 5d, Supplementary Data 3 and
Supplementary Table 4). A heat map of OXPHOS genes showed an
increased expression of electron transport chain genes in CD8+ TM
cells from metformin-treated BCG-vaccinated mice (Supplementary
Fig. 6c).
We next examined whether metformin treatment would
enhance BCG vaccine-mediated Mtb control in mice. A trend
for reduced Mtb bacillary load in the lungs of metformin-treated
vaccinated mice compared to untreated vaccinated mice was
observed (Fig. 5e). BCG-vaccinated metformin-treated mice
showed an increased frequency of memory CD8+ T cells, and
decreased effector CD8+ T cells upon Mtb infection compared to
the BCG-vaccinated mice alone (Supplementary Fig. 6d, upper
panel). When stimulated with class I-restricted peptide (TB10.4)
of the Mtb EsxH gene, memory CD8+ T cells from BCG-
vaccinated metformin-treated mice demonstrated increased TNF
production compared to the BCG-vaccinated mice alone
(Supplementary Fig. 6d, lower panel). We next used the guinea
pig TB model to further evaluate metformin-mediated enhance-
ment of BCG efficacy (Fig. 5f)45. Lung Mtb bacillary load in
metformin-treated BCG-vaccinated guinea pigs was significantly
lower compared to unvaccinated animals or animals which
received only metformin, reduction of 3.4 log10 and 2.9 log10,
respectively (Fig. 5g). In this experiment, bacillary load in
untreated vaccinated animals was not significantly different from
unvaccinated animals (reduction of 0.4 log10, Fig. 5g). Histo-
pathological evaluation of the infected lungs showed reduced
infiltrating leukocytes and lesions in BCG-vaccinated guinea pigs
compared with unvaccinated animals (4.3-fold reduction in lung
lesion burden, Fig. 5h). Importantly, lungs of metformin-treated
BCG-vaccinated guinea pigs showed 11.2- and 2.6-fold reduced
lesion burden compared with the control and untreated BCG-
vaccinated guinea pigs, respectively (Fig. 5h, i). Taken together,
our data suggested that metformin enhances the BCG vaccine
response and efficacy against Mtb.
Metformin expands CD8+CXCR3+ TM cell population in
humans. To investigate the effect of metformin in humans, we
performed CyTOF on peripheral blood mononuclear cells (PBMCs)
from healthy human participants who took a standard dose of
metformin for five days (Fig. 6a, See Methods)46. The PBMCs were
stained with a panel of 38 markers (Supplementary Table 5).
Analysis of CD8+ T cells (CD45+CD14−CD19−HLA-DR+CD3+
CD4− γδTCR−TCRVα7.2-CD161−CD56−CD8+) using t-SNE
(Supplementary Fig. 7a) identified TN cells (CCR7+CD45RO−
CD45RA+), TE cells (CCR7−CD45RO+CD45RA+) and TM cells
(CCR7+CD45RO+CD45RA−) (Fig. 6b, c; Supplementary Fig. 7a)47.
Two distinct TM and TE subgroups were observed (Fig. 6b).
Fig. 3 Metformin promotes CD8+ T-cell SRC, mitochondrial mass, survival, and FAO. a Oxygen consumption rate (OCR) and spare respiratory capacity
(SRC) in spleen CD8+ T cells from control and metformin-treated WT mice in response to different drugs. n= 4 control mice, n= 5 metformin-treated
mice. b OCR in spleen CD8+ T cells from control and metformin-treated Cxcr3−/− mice. n= 6 mice/group. c Mitotracker green staining of CD8+ T cells
from control and metformin-treated WT mice. MFI - median fluorescence intensity. n= 4 mice/group. d TMRM staining of CD8+ T cells from control and
metformin-treated WT mice. n= 4 mice/group. e Experimental schematic of adoptive transfer of CD8+ T cells into congenic WT mice. f Frequency of
CD45.1+ cells in the spleen and lymph node of recipient mice. n= 4 mice/group. g OCR in spleen CD8+ T cells from control and metformin-treated WT
mice in response to different drugs under low glucose (LG) condition in the presence and absence of palmitate. n= 5 mice/group. h, i OCR in spleen CD8+
T cells from metformin-treated WT mice in response to different drugs under LG condition in the presence of palmitate. h n= 5 mice/group; i n= 8 mice/
group. j Glucose uptake (2-NBDG) in CD8+ TM cells, analyzed by flow cytometry. n= 5 mice/group. Data in a, c, d, f, g, and j are presented as mean ± SD,
two-tailed Mann–Whitney U test.
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Interestingly, the TM2 subset was positive for CD127 and CXCR3
(Fig. 6d), similar to what we observed in mouse CD8+ TM cells
(Fig. 2c). This CD8+ TM2 (CD8+CD127+CXCR3+) population
expanded upon metformin intake in healthy subjects (Fig. 6e), and
also showed increased expression of anti-apoptotic BCL2 (Fig. 6f),
which was previously shown to correlate with CD8+ T-cell survi-
val48. We next performed flow cytometric analysis on the PBMCs
from T2D patients who were being treated with either metformin or
with other anti-diabetic drugs as monotherapy (Supplementary
Fig. 7b and Supplementary Table 6). These two groups had similar
fasting plasma glucose levels (Supplementary Table 6). Metformin-
receiving T2D patients showed an increased frequency of CD8+
CXCR3+ TM cells compared with T2D patients treated with other
anti-diabetic drugs (Fig. 6g). Overall, our data indicated that met-
formin induced the expansion of memory-like CD8+CXCR3+
T cells both in mice and humans.
a
d e f
g h i j
b c
Fig. 4 Metformin reprograms gene expression of CD8+ TM cells. a Schematic depicting sorting of CD8+ TM cells for RNA sequencing and identification
of DEGs in metformin-educated CD8+ TM cells. b Molecular function enrichment via Ingenuity pathway analysis (IPA) of DEGs in a. c Heat map displaying
the expression level of 86 genes related to cell death and survival. d Flow cytometric analysis of caspase-1 in splenic CD8+ T cells from Mtb-infected mice
treated or not with metformin. n= 5 mice/group. e Experimental set-up for the transfer of CD8+ TM or TE cells into TCRβδ−/− mice followed by Mtb or
BCG infection. Three experiments were performed. f, g Flow cytometric analysis of the frequency of CD45.1+ lung f and splenic g cells in recipient mice.
n= 4 control group, n= 6 metformin group. h Bacterial load in the lung of Mtb-infected TCRβδ−/− recipient mice. i, j Bacterial load in the lung of BCG-
infected TCRβδ−/− recipient mice. Data of mean ± SD of 4–5 mice per group, Kruskal–Wallis test with Dunn’s multiple correction. Data in d, f, g, and h is
presented as mean ± SD, two-tailed Mann–Whitney U test.
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Fig. 5 Metformin promotes BCG vaccine immunogenicity and efficacy. a PPD-specific response of spleen cells, analyzed by flow cytometry. Data on IFNγ
producing CD8+ T, TM, and TE cells. n= 5 mice/group. Box-and-whisker plot show the median, 5 and 95 percentiles, one-way ANOVA with Turkey’s
multiple comparison test. b, cMitotracker green b TMRM c staining of splenic CD8+ T cells from control and metformin-treated BCG-vaccinated WT mice.
b n= 4 mice/group; c n= 5 mice/group. means ± SD, Mann–Whitney U test. d Changes in gene expression in CD8+ TM cells from BCG-vaccinated mice
treated or not with metformin. IPA analysis of 607 DEGs. n= 5 mice/group. e Schematic ofMtb infection of metformin-treated BCG-vaccinated mice. Lung
bacillary load at 30 days post infection (p.i) is shown. n= 6 mice/group. f Schematic of Mtb infection of metformin-treated unvaccinated and BCG-
vaccinated guinea pigs. g Lung bacillary load in unvaccinated and BCG-vaccinated Mtb-infected guinea pigs treated or not with metformin. n= 6–7
animals/group. h Light micrographs of hematoxylin and eosin (H&E) staining of lung sections from animals in g. Magnification for main image ×40 (scale
bars, 50 μm) and insert ×100. i Morphometric analysis of lung sections shown in h indicating the mean lesion lung involvement from each guinea pig. n=
6–7 animals/group. Data in a–c, e is representative of two independent experiments. Guinea pig data in g and i is from one experiment. Data in e, g, and i,
means ± SD, Kruskal–Wallis test with Dunn’s multiple correction.
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Effect of metformin on Mtb clearance and reactivation. CD8+
T cells play an important role in long-term protective immune
responses against Mtb infection and reactivation of latent TB10,49.
To assess the persistence of metformin effects, we first measured
the bioenergetic profiles of splenic CD8+ T cells from naive mice
that received metformin for 6 months. Similar to our previous
finding (Fig. 3a), OCR was higher in CD8+ T cells from mice
chronically treated with metformin compared with those from
untreated mice (Supplementary Fig. 8a). This was associated with
an increased number of splenic CD8+ TM cells in metformin-
treated mice (Supplementary Fig. 8b). We next used a modified
version of the TB Cornell model50 to evaluate the long-term
effects of metformin on Mtb clearance and reactivation. In this
model, Mtb-infected mice were treated with pyrazinamide (PZA)
and isoniazid (INH) ±metformin for 70 days starting on day 40
p.i., followed by a rest period of 40 days, and then challenged with
dexamethasone to reactivate any persisting bacilli (Supplementary
Fig. 8c). In the animals which received metformin along with
PZA and INH, bacilli was recovered from the lungs of 40–50%
mice sacrificed 40 days after the drugs were stopped (day 150 p.i,
Table 1 and Supplementary Fig. 8c). However for mice which
received only PZA and INH, bacilli were recovered from 75–80%
of animals at day 150 p.i. After 15 days of dexamethasone
treatment bacilli were recovered from the lungs of 20–50% of
mice treated with metformin+PZA+ INH compared with
75–80% mice treated with PZA+ INH (Table 1). Taken together,
these data suggest that metformin enhances the sterilizing activity
a b d e
gfc
Fig. 6 Metformin treatment expands CD8+CXCR3+ TM cell population in humans. a Strategy of analyzing PBMCs from metformin-treated healthy
individuals. b t-SNE map of human peripheral CD8+ T cells with manually cluster gating for TE, TM, and TN cells. c Normalized expression intensities of
indicated markers were calculated and overlaid on the t-SNE plot, characterizing all cluster of human CD8+ T cells. d Manual gating identified differential
expression of CD127 and CXCR3, distinguishing two CD8+ TM subpopulations, TM1 and TM2. e Frequency of CD8+CD127+CXCR3+ TM cells before and
after metformin treatment. n= 8 subjects, analysis by Wilcoxon matched-pairs signed rank test. f Overlay plot showing expression of BCL2 in CD8+
CD127+CXCR3- and CD8+CD127+CXCR3+ TM cells. BCL2 expression in CD8+ TN cells is also indicated. Data shown from one representative donor.
g Flow cytometric analysis of frequency of peripheral CD8+CXCR3+ TM cells in T2D patients receiving either metformin or other diabetic monotherapy,
n= 18 other monotherapy group, n= 42 metformin group. Box-and-whisker plot show the median, 5 and 95 percentiles. Analysis by two-tailed t test with
Welch’s correction.
Table 1 Efficacy of metformin against Mtb in modified
Cornell-mice model.





Exp 1 1/5 (20%)ll 3/5 (60%) 1/5 (20%) 4/5 (80%)
Exp 2 1/4 (25%) 2/4 (50%) 1/4 (25%) 2/4 (50%)
Proportion of mice with no detectable CFUs in the lungs and spleen during PZA+INH therapy
with and without MET in two different experiments. INH isoniazid, PZA pyrazinamide, MET
metformin.
‡Mtb-infected mice were administered INH (10 µg/mL) and PZA (15mg/mL).
llNumber of mouse with no detectable CFU out of total number of animals in that group. In
bracket percentage information is provided.
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of suboptimal antimicrobial treatment for Mtb infection by
boosting intrinsic host immune function.
Discussion
The goals of HDT for TB are to accelerate lesion sterilization and
mitigate immune pathology by educating host anti-Mtb
responses2,51. Previously, we proposed metformin as an adjunc-
tive TB treatment, reporting that it lowers risk for cavitary TB and
mortality in adults with T2D3. In the present study, we showed
that metformin treatment (i) expands CD8+CXCR3+ TM cells in
mice and humans, (ii) reprograms CD8+ T cells metabolic and
transcriptional circuits, (iii) enhances BCG vaccine protective
efficacy, and (iv) improves sterilizing ability of antibiotics, thus
preventing Mtb reactivation.
Metformin-educated Ag-inexperienced CD8+CXCR3+ TM
cells share phenotypic and functional properties with Ag-specific
CD8+ TCM, Ag-inexperienced TVM, innate-memory CD8+ T,
and/or IL-15-derived CD8+ TM cells52, and have enhanced sur-
vival and anti-Mtb properties. Cytokine-activated CD8+ TM cells
are known to contribute to host protection against diverse
pathogens17. The differential transcriptomic and phenotypic
properties of metformin-educated CD8+CXCR3+ TM cells sug-
gest that these cells may represent another type of “innate CD8+
T-cell”17. The CXCR3/CXCL10 axis can shape the distribution of
CD8+ TM cells in the tissues of non-immunized mice53 and
CXCR3-expressing innate CD8+ TM cells are known to express
activation markers, respond to IL-2 and IL-15, and possess
antibacterial effector function54,55. In addition, CXCR3 is
required for the migration and establishment of CD8+ TCM cell
population in the respiratory tract, where they protect against
influenza A virus infection29.
CD8+ TM cells protect the host against infectious diseases by
virtue of their recall ability to expand and execute effector
functions10,56. These responses are promoted by AMP-activated
protein kinase (AMPK)57, a crucial energy sensor and an indirect
target of metformin. AMPK signaling promotes OXPHOS during
CD8+ TM generation58 and maintains mitochondrial health in
TM cells59. This indicates the importance of AMPK and OXPHOS
in rewiring of metformin-educated Ag-inexperienced CD8+ TM
cells in our experiments. We demonstrated that CXCR3 signaling
is required for metformin-mediated induction of OXPHOS in
CD8+ T cells, suggesting a possible CXCR3- and AMPK-
dependent effect(s). How CXCR3 regulates metformin-mediated
induction of OXPHOS, mitochondrial health and expansion of
CD8 memory remains to be determined. Interestingly, mice
devoid of AMPK in CD4+ T cells shows deficiency in the CXCR3
expression60. Our transcriptomic analysis of CD8+ T cells from
Cxcr3−/− mice suggested dependency of metformin-mediated
reprograming of mitochondrial function on Foxo1 network
(Fig. 2i, j), which is an important metabolic check point40. Of
note, TB immunopathology could be modulated by targeting
T cells mitochondrial metabolism61.
The recall ability of TM cells is also the basis for vaccinations
against numerous diseases including TB. The current TB vaccine,
BCG, is unable to protect against pulmonary TB in adults, hence
there is an urgent need to improve BCG or to develop new TB
vaccine. Here we showed that metformin treatment resulted in an
increased (i) elicitation of Ag-specific CD8+ TCM in the tissues of
BCG-vaccinated mice, (ii) TNF secreting Ag-specific CD8+ TCM
cells in the tissues of BCG-vaccinated Mtb-challenged mice, and
(iii) protection of BCG-immunized mice and guinea pig against
Mtb challenge. Importantly, expression of CXCR3 by TB vaccine-
specific CD8+ T cells is needed for their homing to the lung
mucosa62. This raises the possibility of the presence of metformin-
educated CD8+ T cells in different anatomical location within
lung parenchyma, which is responsible for enhanced protective
immunity. We did not see enhanced immunogenicity among
Ag-specific CD4+ TCM cells from metformin-treated BCG-
vaccinated mice, which goes in line with no benefit of metformin-
educated Ag-inexperienced CD4+ T cells on Mtb growth in
adoptive transfer experiments (Fig. 1b, c). The differential effect of
metformin on the CD4+ and CD8+ cells in naive or vaccinated
host is not clear at present. However, as metformin normalizes
CD4+ T-cell mitochondrial function to alleviate lupus in B6.Sle1.
Sle2.Sle3 mice63 and aging-associated inflammation64 in humans,
an effect of metformin on CD4+ T-cell metabolism in Mtb-
infected hosts cannot be excluded. Nevertheless, our results sup-
port the concept of enhancing the efficacy of BCG vaccine by
small molecule drugs65.
In conclusion, the data presented here show that metformin
shifts CD8+ T-cell metabolism, leading to the expansion of a
memory-like CD8+CXCR3+ phenotype with functional proper-
ties that contribute to host control of Mtb infection and disease.
Our findings are in line with evidence that metabolic repro-
graming by metformin reverses CD8+ T-cell dysfunction during
chronic Mtb infection66. Our current and previously reported
studies show that metformin ameliorates TB immune pathology,
whereas others reported that it reverses established pulmonary
fibrosis in the bleomycin model67. That evidence, together with
our demonstration that metformin enhances BCG vaccine
immunogenicity and protective efficacy adds to the basis in evi-
dence supporting metformin as a candidate for TB-HDT and as a
TB vaccine adjunct.
Methods
Healthy human samples. PBMCs were isolated from eight male healthy non-
obese volunteers without medication, kidney function loss, or metabolic disorders,
who had received metformin for 5 days in increasing doses starting at 500 mg once
a day and ending with 1000 mg twice a day46. Blood was drawn at baseline time
point before metformin intake (T0) and immediately after metformin intake on
day 6 (T6).
Diabetic human patient cohort. Patients with T2D included in the study are part
of the Singapore Longitudinal Aging study 2 (SLAS-2), which is a population-based
cohort to study the biology of aging among Singaporean elderly individuals >55
years old68. PBMCs from the blood samples collected from overnight fasting
individuals were washed with PBS and cryopreserved in liquid nitrogen. PBMCs
were thawed and used for flow cytometric staining. Fasting blood glucose, blood
count, hematocrit level, albumin, creatinine, estimated glomerular filtration rate
was performed on the blood samples.
Animals. CD45.1, CD45.2, Cxcr3−/−, TCRβδ−/−, and OT-I mice were obtained
from SIgN mouse core. All mice strains were on C57BL/6 J background. CD45.1
and CD45.2 mice for chimeric in vivo experiments were obtained from Jackson
Labs (Bar Harbor, USA), and performed at UMMS. For all in vivo experiments
female mice aged between 8 and 12 weeks were used. Hartley strain female guinea
pigs aged between 7 and 8 weeks (350–400 g) were obtained from Charles Rivers
(Wilmington, MA), maintained on a normal chow diet, acclimated for 1 week then
randomly assigned to four groups. Animals were housed in the SPF and BSL3
animal facilities on a 12/12 h light/dark cycle, with food and water ad libitum.
Metformin treatment for mice and guinea pigs. Metformin (1,1-Dimethylbi-
guanide hydrochloride, Sigma Aldrich) was provided to mice in drinking water
(1.83 mg/ml which is equivalent to 270 mg/kg). Details of metformin treatment for
different experimental models is provided in the figures. Guinea pigs were treated
with 25 mg/kg of metformin suspended in carrier (Ora-Sweet, Paddock Labora-
tories, Minneapolis, MN), or carrier alone, and administered orally once daily,
for 30 days, prior to Mtb infection. The metformin dose was determined in guinea
pigs based on PK/PD analysis in which the peak plasma concentration reached
1.1 μg/mL (peak plasma concentration in human 1.1 μg/mL).
BCG vaccination. Female mice aged 8–10 weeks were vaccinated subcutaneous
with a single dose BCG Pasteur strain (1 × 106 colony-forming units (CFU) in
100 µl PBS). In BCG-vaccinated mice metformin treatment was initiated 1 day
post vaccination. Guinea pigs were vaccinated intra-dermally (i.d) with 1 × 105
BCG Pasteur strain. In vaccinated guinea pigs metformin treatment was initiated
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14 days post vaccination. Sham vaccinated guinea pigs received an equal volume of
saline i.d.
Mtb infection. Female mice were infected via aerosol or intra tracheal (i.t)69 route
with Mtb H37Rv or Mtb Erdman to deliver 100–200 viable bacilli per lung. For
BCG infection experiments, 10 × 106 BCG bacilli were used. The implanted bac-
terial loads in the lungs of infected mice were quantified 1 day post infection.
Guinea pigs were infected with the Mtb H37Rv by aerosol to deliver 10–20 bacilli
per animal and confirmed by culture.
Modified Cornell model. Starting 40 days p.i Mtb-infected female mice were given
INH (10 µg/mL) and PZA (15 mg/mL) in drinking water ad libitum70 for 70 days.
This was followed by a 40 day rest for all treatments. Subsequently, at day 150 p.i
mice were treated with 1 mg/mL of dexamethasone in drinking water for 15 days.
Culturing of mycobacterial strains.Mtb H37Rv, Erdman, andM. bovis BCG were
grown in Middlebrook 7H9 broth (BBL Microbiology Systems) supplemented with
10% ADS (Albumin, Dextrose, Saline, Sigma) enrichment medium with 140 mM
NaCl, 0.5% glycerol and 0.5% Tween-80 at 37 °C for 5–10 days to an OD600 of
0.4–0.5. Bacterial cultures were harvested, re-suspended in 7H9 broth with 20%
glycerol, and aliquots were frozen at −80 °C until later use. Before infection, cells
were thawed, washed, and sonicated. Viable cell counts per mL in thawed aliquots
were determined by plating serial dilutions on to Middlebrook 7H11 agar plates
supplemented with 10% OADC (Oleic acid, Albumin, Dextrose, Catalase, BBL
Microbiology Systems) and 0.5% glycerol followed by incubation at 37 °C for
three weeks.
Enumeration of Mtb load in the tissues of infected animals. Mycobacterial
loads in lung and spleen of euthanized mice were evaluated at different time points
post infection by homogenizing the organs in PBS or PBS with 0.05% Tween-80
using MACS tissue dissociator (Miltenyi Biotec). Guinea pigs were killed with an
intra-peritoneal overdose of pentobarbital (>120 mg/kg), and representative lung
tissue samples were collected sterilely and homogenized in 9 ml of sterile saline.
Tenfold serial dilutions of tissue homogenates in sterile PBS were plated in tri-
plicates on Middlebrook 7H11 agar plates supplemented with 10% OADC and
0.5% glycerol, incubated for 3–6 weeks at 37 °C and CFUs counted.
Cell isolation from lungs and spleens. Lungs were aseptically isolated from mice
and incubated at 37 °C in 10% FBS RPMI media containing 1.4 mg/ml collagenase
A (Roche) and 30 µg/ml DNase I for 60 min. The treated lung tissue and spleen was
dissociated over the 70 μm cell strainer (Fisherbrand). Strainer was washed to
collect single-cell suspension. Red blood cells were lysed with ACK lysing buffer
(Lonza) for 5 min following by washing of cells with culture media. Cells were
counted and adjusted to 5 × 106 cells/ml.
Magnetic sorting of murine T cells. Spleen cells were washed twice in fresh
magnetic-activated cell sorting (MACS) buffer. CD4+ and CD8+ T cells were
magnetically purified via negative selection using Dynabeads or MACS cell
separation system (Supplementary Table 7) according to the manufacturer’s pro-
tocols, followed by purity check which was around 90-95%.
FACS sorting of murine memory CD8+ T cells. MACS-sorted splenic CD8+
T cells were stained with live dead marker, blocked with Fc block and surface
stained with anti-CD3-FITC, anti-CD4-Pacific blue, anti-CD8-APC-Cy7, anti-
CD44-BV650, and anti-CD62L-PE-Cy7 (Supplementary Table 8). Stained cells
were sorted on fluorescence-activated cell sorting (FACS) Aria II, FACS Aria III,
or BD Influx (Becton Dickinson, San Jose, CA, USA), followed by purity check
which was ~90–95%.
Adoptive T-cell transfers. Purified splenic CD4+ or CD8+ T cells from untreated
or metformin-treated CD45.1 WT or CD45.2 WT mice were transferred via tail
vein injection into sub lethally irradiated (600 rads) CD45.2 WT mice (Fig. 1).
MACS-sorted splenic CD8+ T cells or TM or TE from untreated or metformin-
treated CD45.1 WT mice were transferred via intra orbital injection into CD45.2
WT or Tcrβδ−/− (Fig. 3d, e). The details of number of T cells transferred are in
Supplementary Table 9.
Metabolism assays. Real-time mitochondrial OCR and ECAR of splenic CD8+
T cells was measured in media (Dulbecco’s modified eagle medium; DMEM
containing 25 mM glucose and 2 mM L-glutamine), in response to 1 µM oligomycin,
5 µM FCCP, and 0.5 µM rotenone/antimycin A, using Seahorse XF Cell Mito Stress
and Glyco Stress Test Kit and XFe96 Extracellular Flux Analyzer (Agilent Tech-
nologies, USA, Supplemental Table 7). FAO assay were carried out using Seahorse
XF Palmitate-BSA FAO Substrate kit in media (KHB containing 2.5 mM glucose
and 0.5 mM Carnitine) in response to 1 µM oligomycin, 1 µM FCCP, and 0.5 µM
rotenone/antimycin A. For FAO assay, cells were prior starved in Seahorse DMEM
medium (DMEM containing 0.5 mM glucose, 1 mM L-glutamine, and 0.5 mM
Carnitine) for 2 hrs. Also for FAO assay, BSA or Palmitate:BSA was added into the
96-well plate and 200 µM etomoxir were used additionally as drug injection. SRC
was determined as the absolute increase in OCR after FCCP injection compared
with basal OCR. Data was analyzed with Wave software, version 2.4 (Agilent
Technologies).
Flow cytometry. Single-cell suspensions of spleens, lungs, and lymph nodes (from
mice) were prepared at the indicated time points. Live dead staining was performed
for 15 minutes at room temperature or for 20 minutes at 37 °C. Non-specific
antibody binding was blocked by adding anti-CD16/32 (Fc block) (BD Bios-
ciences). Following this surface markers were stained for 20–25 minutes at 4 °C
with the following anti-mouse antibodies: anti-CD45-Pacific blue/BV605/ FITC,
CD45.1-BV711, CD45.2-APC, anti-CD3-FITC/ Pacific blue/ BUV395/ PerCP-
Cy5.5, anti-CD4-Pacific blue/Alexa Fluor 700/PerCP-Cy5.5/PE, anti-CD8-APC-
Cy7/ FITC, anti-CD44-BV650/ PE-Cy7/ PE-Cy5, anti-CD62L- PE-Cy7/ PE-CF594
and anti-CXCR3-BV605 (Supplementary Table 8). In some experiments, mito-
chondrial staining was performed with 200 nM Mitotracker green and/or 20 µM
TMRM in RPMI media without FCS for 30 minutes at 37 °C prior to staining of
surface markers.
For intracellular cytokine staining, spleen cells were ex vivo stimulated for 20 h
with 40 μg/ml PPD (purified protein derivative, Statens Serum Institute, Denmark)
in the presence of Golgi StopTM (BD Biosciences) and Monensin (1000×,
BioLegend) for the last 4 hours, at 37 °C and 5% CO2. In some experiment’s spleen
cells were ex vivo stimulated with IL-2 and TB10.4 peptides for 5 hours at 37 °C.
Brefeldin A was added to the stimulation for the last 4 hours. Live dead staining
and blocking was performed. Cells were then stained with anti-CD45-BV605, anti-
CD3-Pacific blue/PerCP-Cy5.5, anti-CD4-PE/Alexa Fluor 700, anti-CD8a-APC-
Cy7/FITC, anti-CD44-PE-Cy7/PE-Cy5 and anti-CD62L-AlexaFluor 700/PE-Cy7
antibodies for 25 min at 4 °C (Supplementary Table 8). After washing, cells were
fixed and permeabilized for 20 minutes with Cytofix/CytopermTM (BD
Biosciences). Permeabilized cells were washed with Perm/Wash bufferTM (BD
Biosciences) and stained with anti-IFN-γ-APC/BV 421, TNF-APC or Perforin-PE
antibody for 25 minutes at 4 °C. Subsequently, cells were fixed in 2%
paraformaldehyde before acquisition.
Human PBMCs were stained with live dead marker and following anti-human
antibodies: anti-CD34-PE, anti-CD4-BV750, anti-CD8-BV605, anti-CD14-BV605,
anti-TCRγ/δ-APCR700, anti-CD27-BV510, anti-CD45-BUV805, anti-CxCR3-
BV650, anti-TCRVδ2-BV711, anti-CD3-BV570, anti-Vα7.2-APC-Cy7, anti-
CD45RO-PerCP/Cy5.5, and anti-CD161-BV785 (Supplementary Table 10).
Dilution of different antibodies used was either 1:50, 1:100, or 1:200. Each antibody
was validated for flow cytometry staining as per manufacturer’s description.
Fluorescence-minus-one and isotype controls were used during validation. Stained
cells were acquired using a LSRII cytometer with five lasers (BD, San Jose, CA,
USA) or Fortessa cytometer with four lasers (Becton Dickinson, San Jose, CA,
USA) or Symphony cytometer (BD Biosciences, California, USA) and data was
collected using FACSDivaTM version 7 (BD Biosciences). Flow cytometry data were
analyzed with FlowJoTM version 10.3 (Tree Star, Inc., USA).
Assessment of caspase-1 activity. The activity of caspase-1 was determined
using fluorescent inhibitor of caspase-1 (FAM-Flica Caspase-1 Assay kit, Immu-
noChemistry Technologies). Staining procedure was performed according to
manufactures protocol. In brief after live/dead and surface antibody staining of
lung and spleen single cells, FLICA reagent FAM-YVAD-FMK was provided to
single cells and binding to activated caspase-1 was allowed for 1 h at 37 °C in the
dark. Stained cells were washed with apoptosis wash buffer, followed by fixation.
The green fluorescent was detected in FITC channel and samples were acquired
using LSRII cytometer.
Glucose uptake assay. 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deox-
yglucose (2-NBDG) uptake was performed on glucose-deprived cultures of spleen
and lung single cells. Cells were incubated in media containing 200 µM 2-NBDG
for 20 minutes at 37 °C. Followed this live dead and surface marker staining was
performed. Fluorescent of 2-NBDG was detected in FITC channel using Fortessa
cytometer.
CyTOF staining and data analysis. Spleen and lung cells from mice, and human
PBMCs were first stained with 200 µM cisplatin (Sigma) for the discrimination of
dead cells. Upon this, cells were washed and stained with a primary antibodies
cocktail for 30 minutes at 4 °C (Supplementary Table 1 (for human antibodies) and
Supplementary Table 5 (for mouse antibodies)). Dilution of different antibodies
used was either 1:100 or 1:200 and was standardized by our CyTOF platform.
After washing, cells were stained with the heavy metal-labeled antibodies cocktail
for 30 minutes at 4 °C. Cells were washed, fixed and permeabilised using fixation
FoxP3 buffer (eBioscience) for 45 minutes at 4 °C. Upon this cells were stained with
intranuclear antibodies cocktail for 30 minutes at 4 °C. Labeled cells were washed
twice with PBS and fixed in 2% or 4% PFA overnight. Subsequently, cells were
washed and stained for barcodes (30 minutes at 4 °C) and DNA (10 minutes at
4 °C). Samples were acquired on the Helios CyTOF (Fluidigm), and analyzed as
mentioned before24,25,71. For details, see supplementary methods.
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Ex vivo culture of primary T cells. OT-1 splenocytes were activated with 20 µg/ml
OVA protein (Invivogen) and 100 U/ml hIL-2 (Miltenyi Biotec) and cultured in
IMDM media (supplemented with 10% FBS, 2 mM L-glutamine, 1 mM Sodium
pyruvate, 0.1 mM NEAA, 1% Kanamycin) for 3 days. After washing, cells were
subsequently cultured with 0.4, 2, 10 ng/ml of hIL-15 (R&D) and/or 2 mM MET
for 4 days. IL-15-derived antigen-specific CD8+ T cells were analyzed for memory
markers by flow cytometry.
Real-time quantitative RT-PCR. Cells or tissues were lysed in TRIzol Reagent
(Invitrogen), and total RNA was extracted using the RNeasy Mini Kit (Qiagen).
RNA was reverse-transcribed using the iScript cDNA synthesis Kit (Bio-Rad).
Complementary DNA (cDNA) was used for real-time quantitative PCR using 2x
iQ SYBR Green supermix and C1000 Thermal Cycler (Bio-Rad) using specific
primers (see supplemental methods). The relative mRNA expression level of each
gene was normalized to Gapdh housekeeping gene expression in the untreated
condition, and fold induction was calculated by the ΔΔCT method relative to those
in untreated cells per tissue.
RNAseq and analysis. Total RNA was extracted following the double extraction
protocol: RNA isolation by TRIzol followed by a Qiagen RNeasy Micro clean-up
procedure (Qiagen, Hilden, Germany). The extracted RNA samples were inspected
on Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA) for quality
assessment. All RNA samples were analyzed on Perkin Elmer Labchip GX system
(Perkin Elmer, Waltham, MA, USA) for quality assessment with a median RNA
Quality Score of 9. cDNA libraries were prepared using 500 pg of total RNA and
1ul of a 1:200,000 dilution of ERCC RNA Spike in Controls (Ambion, Thermo
Fisher Scientific, Waltham, MA, USA) using SMARTSeq v2 protocol72 except for
the following modifications: 1. Use of 20 µM TSO; 2. Use of 250 pg of cDNA with
1/5 reaction of Illumina Nextera XT kit (Illumina, San Diego, CA, USA). The
length distribution of the cDNA libraries was monitored using DNA High Sensi-
tivity Reagent Kit on the Perkin Elmer Labchip GX system (PerkinElmer, Wal-
tham, MA, USA). The libraries were qPCR quantified (Kapa Biosystems,
Wilmington, MA) to ascertain the loading concentration. RNAseq libraries of
FACS sorted CD8 TM cells subjected to an indexed PE sequencing run of 2 × 51
cycles on an Illumina HiSeq 2000. FASTQ files were checked for quality control
issues using fastQC and none were found. The reads in the FASTQ files were
mapped onto the mouse genome build mm10 using STAR and the gene counts
counted using featureCounts (part of the Subread package). DEGs were detected
using DESeq273 running in R version 3.3.3. DEGs having a p value <0.05 (calcu-
lated by DESeq273 using t test) were considered to be statistically significant. DEGs
were used in IPA for a core analysis. IPA uses Fisher’s exact test to determine the
probability of the association of genes with the pathway/molecular function. Heat
maps were generated using the package ComplexHeatmap in R version 3.3.3.
Enrichment of FOXO1 targets. The overlap between the DEGs from the RNAseq
comparison of CD8+ T cells from Cxcr3−/− vs WT mice and the FOXO1 target
genes from Webb et al.36 was determined (Supplementary Data 1). The hyper-
geometric distribution was used to determine the significance of this overlap/
enrichment using all the RNAseq genes tested and the genes analyzed in Webb
et al.36 as the background. A p value of <0.05 was considered to be significant.
Analysis conducted in R version 3.3.3.
Histology and morphometry of guinea pigs lung samples. Left caudal lung lobe
of guinea pigs was collected for histopathology and was fixed in 4% paraf-
ormaldehyde for >48 hours, processed and embedded in paraffin, sectioned and
stained with hematoxylin and eosin. The Mtb lesion burden was determined
morphometrically using the area fraction fractionator method with Stereo inves-
tigator software (MBF Biosciences, Williston, VT). The data was expressed as the
percent of lung area affected by characteristic Mtb lesions. Photomicrographs were
obtained from tissue sections representative of the mean values within individual
animal treatment groups.
Statistical analysis. All values are mean ± SD or SEM of individual samples. Data
analysis was performed with GraphPad Prism Software (GraphPad Software Inc.,
version 7.01). The statistical tests utilized are two-tailed and respective details have
been indicated in figure legends.
Study approval. The study was approved by the Institutional Biosafety Committee
(IBC) and Institutional Animal Care and Use Committee (IACUC) of the (i)
Biological Resource Council (BRC), A*STAR, Singapore; (ii) Defence Science
Organization (DSO) national laboratories, Singapore, (iii) Colorado State Uni-
versity, USA, and (iv) University of Massachusetts Medical School (UMMS), USA.
The study in human healthy volunteers and diabetic patients was approved by the
Arnhem-Nijmegen Ethical Committee (NL47793.091.14) and National University
of Singapore Institutional Review Board (NUS-IRB #04-140), respectively.
Informed consent from all participants was obtained.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNAseq data that support the findings of this study have been deposited in GeneBank
GEO, accession GSE139948. Other data are available from the corresponding author
upon request.
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